Table 5.
Elevated amylase or lipase of 29 patients with COVID-19.
| Enzymes | Amylase | Lipase | ||||
|---|---|---|---|---|---|---|
| Normal(10) | 1–3 ULN(8) | >3 ULN(11) | Normal(1) | 1–3 ULN(12) | >3 ULN(16) | |
| Cmax (Mean ± SD) | 92.3 ± 23.0 | 220.6 ± 39.3 | 819.2 ± 334.5 | 46 | 121.2 ± 30.0 | 355.8 ± 169.5 |
| Median (U/L) | 94.5 | 222.5 | 690 | 46 | 123 | 295 |
| Time to Max (d) | 6.2 ± 5.0 | 14.9 ± 12.3 | 15.0 ± 11.0 | 20 | 9.9 ± 12.0 | 17.5 ± 10.6 |
| Median (d) | 6.5 | 16.5 | 12 | 20 | 7.5 | 13 |
ULN, upper limit of normal; SD, standard deviation; Cmax, maximum concentration; Max, maximum. Twenty-nine patients with elevated pancreatic enzymes did not develop pancreatitis. Elevated pancreatic enzymes were seen in 58.2% of critically ill COVID-19 patients, and >3 × ULN in 40%.